Listings

In this section

Events

Excellence Awards

Innovation Rankings

Buyer's Guides

07/26/2024 08:01:36
  • Home | Left in limbo: When pharma halts rare disease research
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Faravelli
  • In Depth
  • Left in limbo: When pharma halts rare disease research
  • Capturing the genAI boom for drug development
  • Too much data: a burden or a blessing?
  • South Korea seeks to accelerate drug reimbursement administration process
  • Sponsors must take on FDA’s diversity guidance to improve community trust
  • DelSiTech Company Insight
  • Thematic Take: Cybersecurity
  • Thematic Take: contents
  • Foreword: Cybersecurity in the age of AI
  • Navigating the AI-driven cybersecurity landscape
  • Key trends impacting cybersecurity
  • Timeline: a history of cybersecurity
  • Explainer: The most common types of cyberattacks
  • The impact of cybersecurity on healthcare
  • Case studies: cybersecurity in healthcare
  • Leading cybersecurity adopters and providers in healthcare
  • AI attacks now ‘the main cybersecurity concern’ for businesses across sectors
  • The state of cybersecurity: AI and geopolitics mean a bigger threat than ever
  • Companies’ own AI applications are ‘a huge cybersecurity problem’
  • How healthcare cybercrime is predicted to escalate
  • The lasting impacts of the pandemic on cybersecurity in healthcare
  • Cyberattacks on healthcare: Russia’s tool for mass disruption
  • Traceability technologies tighten supply chain fakery
  • Deal activity related to cybersecurity in the pharma industry since 2021 
  • Regulators must protect the cybersecurity market from a private equity takeover
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • Xylem
  • Listings
  • Events
  • Excellence Awards
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
07/25/2024 00:00:00